What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - KFF
FDA allows Florida to import certain prescription drugs from Canada, potentially lowering costs but raising supply chain and quality concerns for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; program implementation expected within months, with potential for other states to follow.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA approved Florida's plan to import drugs from Canada under Section 804 of the FD&C Act, creating a new pathway for lower-cost imports that may disrupt existing market dynamics and supply chains.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review importation program details, assess impact on pricing and distribution, and ensure compliance with cGMP and DSCSA requirements if participating or affected.
Deadline
Ongoing; program implementation expected within months, with potential for other states to follow.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)